Icosavax Announces Positive Topline Interim Phase II Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

Icosavax, Inc. announced positive topline interim results from its Phase II clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.